Protagonist Therapeutics (MEX:PTGX) Total Liabilities: MXN757 Mil (As of Mar. 2026)

What is Protagonist Therapeutics Total Liabilities?

Protagonist Therapeutics MEX:PTGX 47 Total Liabilities is MXN757 Mil as of Mar. 2026. GuruFocus rates MEX:PTGX with a GF Score™ of 47/100 and a GF Value™ of MXN751.22. The stock has 7 warning signs investors should review.

Protagonist Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 was MXN757 Mil.

Protagonist Therapeutics's quarterly Total Liabilities declined from Sep. 2025 (MXN1,031.88 Mil) to Dec. 2025 (MXN962.96 Mil) and declined from Dec. 2025 (MXN962.96 Mil) to Mar. 2026 (MXN757.12 Mil).

Protagonist Therapeutics's annual Total Liabilities increased from Dec. 2023 (MXN361.11 Mil) to Dec. 2024 (MXN1,448.01 Mil) but then declined from Dec. 2024 (MXN1,448.01 Mil) to Dec. 2025 (MXN962.96 Mil).

Protagonist Therapeutics Total Liabilities Related Terms

Protagonist Therapeutics Total Liabilities Historical Data

* Premium members only.

The historical data trend for Protagonist Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Protagonist Therapeutics Total Liabilities Chart

Protagonist Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Total Liabilities

Get a 7-Day Free Trial

977.98

630.11

361.11

1,448.01

962.96

Protagonist Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Total Liabilities	Get a 7-Day Free Trial															1,085.92	941.23	1,031.88	962.96	757.12

47GF Score

Protagonist Therapeutics Inc MEX:PTGX

Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Protagonist Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Protagonist Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	818.197	+	(144.766	+	-2.8421709430404E-14
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	963

Total Liabilities	=	Total Assets (A: Dec. 2025 )	-	Total Equity (A: Dec. 2025 )
	=	12031.193	-	11068.23
	=	963

Protagonist Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	623.012	+	(134.109	+	2.8421709430404E-14
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	757

Total Liabilities	=	Total Assets (Q: Mar. 2026 )	-	Total Equity (Q: Mar. 2026 )
	=	12577.069	-	11819.948
	=	757

Frequently Asked Questions Learn more about Total Liabilities →

What does a Total Liabilities of MXN757 Mil mean?

Protagonist Therapeutics (MEX:PTGX) has a Total Liabilities of MXN757 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Protagonist Therapeutics and its competitors.

Is Protagonist Therapeutics' Total Liabilities too high?

Protagonist Therapeutics' current Total Liabilities is MXN757 Mil. Overall, Protagonist Therapeutics has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.

How does Protagonist Therapeutics' Total Liabilities compare to IMVT and SYRE?

Protagonist Therapeutics' Total Liabilities of MXN757 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Total Liabilities for a Biotechnology company?

A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Total Liabilities mean?

A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Protagonist Therapeutics and its competitors. Protagonist Therapeutics's current Total Liabilities is MXN757 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Protagonist Therapeutics stock overvalued right now?

Protagonist Therapeutics (MEX:PTGX) has a current Total Liabilities of MXN757 Mil. The stock's GF Value™ is MXN751.22, compared to a current price of MXN1,565.33 — trading 108.4% above its estimated fair value. The current Total Liabilities is MXN757 Mil. Protagonist Therapeutics' overall GF Score™ is 47/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Total Liabilities calculated?

Total Liabilities is calculated from a company's financial statements. For Protagonist Therapeutics (MEX:PTGX), the current Total Liabilities is MXN757 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Protagonist Therapeutics (MEX:PTGX) Overvalued in 2026?

Based on GuruFocus' analysis, Protagonist Therapeutics stock appears to be overvalued. The current stock price of MXN1,565.33 is trading 108.4% above its estimated GF Value™ of MXN751.22.

Key valuation signals for MEX:PTGX:

Total Liabilities: MXN757 Mil
GF Value™: MXN751.22 vs. price of MXN1,565.33 (108.4% above fair value)
GF Score™: 47/100 with 7 warning signs

No single metric tells the full story. See the MEX:PTGX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Protagonist Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies IMVT SYRE MIRM RYTM PCVX TGTX PTCT HALO KYMR IBRX VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges PTGX:USA

Address 7707 Gateway Boulevard, Suite 140, Newark, CA, USA, 94560

Website https://www.protagonist-inc.com

Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.

47GF Score

Get the complete analysis for MEX:PTGX

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,565.33

Price

MXN751.22

GF Value

View MEX:PTGX Analysis

See Total Liabilities data for all stocks →